focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Agreement signed with Empiric Logic

15 Oct 2019 07:00

RNS Number : 8397P
Open Orphan PLC
15 October 2019
 

15 October 2019

Open Orphan plc

("Open Orphan" or the "Company")

Open Orphan signs agreement with Empiric Logic

 

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce it has signed a new strategic collaboration agreement ("the Collaboration") with Empiric Logic to build on the earlier work performed by Open Orphan and complete the build out of Open Orphan's Health Data platform, Europe's first rare disease, advocacy-led genomic database.

Empiric Logic, a leading managed software service company which provides software to the Life Sciences, Pharma, Pharma Services and Biotech sectors, will incorporate its propriety, privacy preserving, and artificial intelligence enabled software into Open Orphan's Health Data platform to aid the collection and management capabilities of the software.

The Collaboration is the final stage in the completion of Open Orphan's Genomic Health Data platform and will speed up its launch. The platform builds on the genomic analysis, database architecture know-how and prior professional experience between the founders of Empiric Logic and Maurice Treacy, Chief Commercial Officer at Open Orphan.

Cathal Friel, Chief Executive of Open Orphan commented:

"This is an exciting step towards the completion of our genomic Health Data platform, and we are delighted to have Empiric on board to help us quickly and securely become one of the largest databases of rare disease patients in Europe."

Gareth O'Sullivan, CEO at Empiric Logic commented:

"Empiric Logic is delighted to be supporting the Open Orphan team with the final steps of preparing the Genomic Health Data platform to accept first data.

As part of the rollout of the Open Orphan database, it will be making substantial use of our artificial intelligence capabilities, such as for identification of rare-disease genetic mutations, but also for the potential identification of patients for clinical trials going forward."

Enquiries:

Open Orphan plc Tel: +353 1 644 0007Cathal Friel, Chief Executive Officer

Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: +44 (0)20 3757 4980Tom Huddart / Billy Clegg / Dan Sherwen

 

Notes to Editors on Open Orphan:

Open Orphan plc is a European-focused, rare and orphan drug consulting services platform. The Company intends to roll up a number of orphan drug services business. Open Orphan has two data driven digital platforms, a Genomic Health Data Platform, which is establishing a rare disease database and a Virtual Rep platform enabling pharmaceutical companies to engage key opinion leaders and physicians. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.

Notes to Editors on Empiric Logic:

Empiric Logic is a platform provider for health and genomics data analysis. This platform uses proprietary analysis software to automate key aspects of the collation, correlation and analysis of complex health and genomics data. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
AGRMIBFTMBABBBL
Date   Source Headline
11th Jun 20207:00 amRNSMajor New Contract Signed
10th Jun 20205:40 pmRNSHolding(s) in Company
10th Jun 20205:35 pmRNSHolding(s) in Company
10th Jun 20205:30 pmRNSHolding(s) in Company
4th Jun 20207:00 amRNSLaunch of Covid-19 Antibody Testing
29th May 20208:00 amRNSEuronext Growth Dublin Notice
22nd May 202010:53 amRNSResults of Fundraising
22nd May 20207:01 amRNSPrimaryBid.com Offer
22nd May 20207:00 amRNSProposed Fundraising to raise up to £12 million
18th May 20209:05 amRNSSecond Price Monitoring Extn
18th May 20209:00 amRNSPrice Monitoring Extension
18th May 20207:00 amRNSUpdate on antibody test and share price movement
11th May 20207:00 amRNSAppointment of Joint Broker
11th May 20207:00 amRNSNew COVID-19 Antibody Testing Partnership
4th May 20207:00 amRNSMajor New Contract and Directorate Change
23rd Apr 20207:00 amRNSTesting of anti-viral for treating COVID-19
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:01 pmRNSPrice Monitoring Extension
23rd Mar 20204:43 pmRNSSecond Price Monitoring Extn
23rd Mar 20204:37 pmRNSPrice Monitoring Extension
20th Mar 20202:06 pmRNSSecond Price Monitoring Extn
20th Mar 20202:00 pmRNSPrice Monitoring Extension
16th Mar 20207:00 amRNSPublication of positive results in journal
12th Mar 20203:32 pmRNSHolding(s) in Company
12th Mar 20209:00 amRNSHolding(s) in Company
12th Mar 20208:00 amRNSEuronext Growth Dublin Notice
10th Mar 20207:00 amRNSPublication of Positive Results in Journal
9th Mar 20204:53 pmRNSCompletion of Compulsory Acquisition of Shares
9th Mar 20207:00 amRNSCoronavirus Challenge Study Model
6th Mar 20207:00 amRNSNew Contract
3rd Mar 20208:00 amRNSEuronext Growth Dublin Notice
2nd Mar 20203:25 pmRNSChange in Registered Office
27th Feb 20207:00 amRNSAppointment of new Director
26th Feb 20203:04 pmRNSResult of Rule 15 Offer and Total Voting Rights
21st Feb 20207:00 amRNSInvestor Event Attendance and Presentation
20th Feb 20207:00 amRNSAppointment of Chair of Advisory Board
20th Feb 20207:00 amRNSAppointment of Chair of Advisory Board
13th Feb 20207:00 amRNSAppointment of Group Chief Financial Officer
11th Feb 20208:00 amRNSEuronext Growth Dublin Notice
10th Feb 202011:17 amRNSValue the Markets Webinar
7th Feb 20206:08 pmRNSHolding(s) in Company
7th Feb 20203:42 pmRNSSignificant shareholder
7th Feb 20207:00 amRNSInvestor Event Attendance and Presentation
6th Feb 20209:30 amRNSTotal Voting Rights
6th Feb 20208:00 amRNSEuronext Growth Dublin Notice
6th Feb 20207:00 amRNSUpcoming Investor Events
5th Feb 202011:00 amRNSExercise of Warrants and Issue of Shares
3rd Feb 202010:30 amRNSNew Corporate Presentation
31st Jan 202011:23 amRNSResults of Placing and Subscription
31st Jan 20207:00 amRNSProposed Placing to raise a minimum of £5 million

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.